EULAV Asset Management’s Charles River Laboratories CRL Stock Holding History

EULAV Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,000	Closed	-$3.43M	–	188
2023 Q1	$3.43M	Hold	17,000	–	–	0.14%	133
2022 Q4	$3.7M	Hold	17,000	–	–	0.16%	123
2022 Q3	$3.35M	Hold	17,000	–	–	0.15%	132
2022 Q2	$3.64M	Hold	17,000	–	–	0.15%	141
2022 Q1	$4.83M	Hold	17,000	–	–	0.14%	140
2021 Q4	$6.16M	Hold	17,000	–	–	0.16%	140
2021 Q3	$7.01M	Hold	17,000	–	–	0.19%	131
2021 Q2	$6.29M	Hold	17,000	–	–	0.17%	135
2021 Q1	$4.93M	Buy	17,000 +1,000	+6%	+$278K	0.13%	155
2020 Q4	$4M	Buy	16,000 +10,000	+167%	+$2.38M	0.1%	170
2020 Q3	$1.36M	Hold	6,000	–	–	0.04%	220
2020 Q2	$1.05M	Buy	+6,000	New	+$958K	0.03%	230

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

EULAV Asset Management's CRL Position: Q2 2023 in Review

EULAV Asset Management sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 17,000 shares — an estimated $3.43M sold.

EULAV Asset Management first reported a position in CRL in Q2 2020 and held it in 12 quarters. The position peaked at $7.01M in Q3 2021. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

EULAV Asset Management reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
EULAV Asset Management sold 17,000 Charles River Laboratories shares in Q2 2023, an estimated $3.43M.
EULAV Asset Management first reported a position in Charles River Laboratories in Q2 2020 and held it in 12 quarters.
EULAV Asset Management's Charles River Laboratories position peaked at $7.01M in Q3 2021.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on EULAV Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.